Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 18,000 shares, a decrease of 67.8% from the September 30th total of 55,900 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is presently 0.0 days.
Exicure Stock Up 1.7 %
Shares of XCUR traded up $0.04 during mid-day trading on Friday, hitting $2.37. The stock had a trading volume of 8,581 shares, compared to its average volume of 487,722. The company has a market cap of $20.50 million, a PE ratio of -1.56 and a beta of 1.28. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $6.00. The company’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $1.06.
Exicure (NASDAQ:XCUR – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter.
Insider Buying and Selling at Exicure
About Exicure
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Featured Articles
- Five stocks we like better than Exicure
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- ESG Stocks, What Investors Should Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- EV Stocks and How to Profit from Them
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.